Global experts and investors set to explore the booming $600 billion longevity mega-trend in two-day event.
The Founders Longevity Forum is set to take place in Singapore in just two weeks; bringing together leading scientists, investors and industry stakeholders, the event will examine investment opportunities in the fast-growing longevity sector, a market projected to reach $600 billion. Hosted at the intersection of biotechnology, healthcare and financial markets, the forum will provide a platform for discussions on emerging technologies, preventative healthcare strategies and the evolving role of AI in drug discovery.
Singapore’s selection as the venue reflects its status as a hub for health innovation and investment in the Asia Pacific region; the city-state has positioned itself as a key player in longevity research, with institutions such as the National University of Singapore (NUS) – a co-host of the event – driving advancements in geroscience and precision medicine. The forum’s agenda will feature prominent experts and thought leaders addressing both the scientific and commercial aspects of longevity, highlighting developments in biological age diagnostics, geroprotection and biotech investment returns.
Longevity.Technology: The Asia Pacific region is witnessing a rapid acceleration in longevity-focused research and investment; with an aging population and increasing interest in preventative health solutions, events such as the Founders Longevity Forum – co-hosted by Founders Forum, NUS and Longevity.Technology – serve as a critical platform to discuss emerging trends, foster collaborations and examine commercial opportunities in the field.
You can check out the full list of speakers HERE and the agenda HERE but here are a few highlights to whet your appetite…
Exploring the future of longevity research and investment
David Dodick, Chief Science and Medical Officer at Atria, will provide an introduction to the longevity landscape, looking at the scientific, medical and investment opportunities within the sector. Andrea Maier, Co-Director of the NUS Academy for Healthy Longevity, will present on the realization of prevention, exploring how preventive strategies and interventions are shifting the paradigm of aging research.
Hannah Went, Director of Operations at TruDiagnostic, will address the clinical application of biological gerodiagnostics – biomarkers that assess biological aging and risk factors for age-related disease; this is an area of increasing interest as diagnostic technologies improve and precision geromedicine becomes more viable. Andrea Maier will return to discuss the infrastructure required to support precision geromedicine, emphasizing the need for interdisciplinary collaboration and investment in scalable solutions.
AI and machine learning are playing an expanding role in drug discovery; Frank Pun, Head of Insilico Hong Kong at Insilico Medicine, will present on AI-driven approaches to pharmaceutical development, discussing how computational methods are reshaping drug design and accelerating research into therapeutics for aging-related diseases. Investors will also gain insight into the financial landscape of longevity biotech, with Jerry McLaughlin of Life Biosciences examining return on investment in aging biotechnology.
Key developments in gerodiagnostics, supplements and investment
A series of panel discussions will bring together diverse perspectives from researchers, entrepreneurs and investors; David Dodick, Jeremy Lim (CEO of Ameli) and Jens Eckstein (Investment Partner at Hevolution) will discuss the role of gerodiagnostics in clinical settings, examining differing viewpoints on their application and utility in healthcare systems.
A panel on global brands and longevity will feature Iryna Kremin, Founder and CEO of INNOCOS, alongside Luc Aguilar, R&D Director for Microbiome, Exposome and Longevity Domains at L’Oréal; moderated by Longevity.Technology’s CEO, Phil Newman, this session will explore how multinational corporations are integrating longevity science into consumer health and wellness products.
The forum will also address the scientific and regulatory challenges of supplement formulation; Greg Macpherson, Founder of SRW Laboratories, Siobhan Mitchell, Chief Scientific Officer at MitoQ, and Louis Island, Head of Partnerships and Innovation at the Centre for Healthy Longevity at NUS, will discuss the development and quality assurance of longevity-focused supplement molecules.
Industry leaders to reflect on key longevity trends
The event will close with a discussion featuring high-profile figures in healthcare and investment; the KOL (Key Opinion Leader) panel will include Dodick, Nicole Sirotin (CEO of the Institute for Healthier Living Abu Dhabi), David Luu (Founder and CEO of Hearty) and Jordan Schlain (Founder and Chairman of Private Medical). Their discussion will offer insights into the evolving priorities of longevity-focused healthcare providers and their role in shaping future medical interventions.
A fireside chat on biotech investing in longevity will bring together Peter Fedichev of Gero.ai and Jens Eckstein of Hevolution; their conversation will provide a financial and strategic perspective on investing in longevity technologies, fostering innovation, addressing risk, return potential and the long-term impact of biotech innovations on healthcare markets.
With just two weeks until the Founders Longevity Forum opens in Singapore, the event promises to be a significant gathering for those invested in the future of longevity; combining scientific expertise with investment acumen, the forum will provide a comprehensive view of the latest developments in longevity research, diagnostics and therapeutics – an essential meeting point for those shaping the industry’s next phase.
Don’t miss out on Founders Longevity Forum Singapore – secure your spot today!
